Could a common Anti-Inflammatory pill boost biologic therapy for ulcerative colitis?
NCT ID NCT05205603
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether adding mesalazine (a standard anti-inflammatory drug) to biologic treatments like infliximab or vedolizumab helps people with moderate to severe ulcerative colitis achieve endoscopic remission (healing of the gut lining). The trial enrolled 438 adults and followed them for 12 months. The goal is to see if the combination works better than biologics alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mesalazine combined with a biologic (infliximab or vedolizumab)
What this could lead to
If it works, this could show that adding mesalazine to standard biologic therapy helps more people achieve endoscopic remission, potentially improving long-term disease control.
What could go wrong
This is a Phase 4 study, so the drugs are already approved, but the benefit of adding mesalazine is unclear. The trial is completed but results are not yet reported, so we don't know if the combination is truly better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Shantou University Medical College
Shantou, Guangdong, China
-
First People's Hospital of Foshan
Guangzhou, Guangdong, China
-
General Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China
-
Guangzhou Panyu Central Hospital
Guangzhou, Guangdong, China
-
Nanhai Hospital, Southern Medical University
Guangzhou, Guangdong, China
-
People's Hospital of Chongqing
Chongqing, Chongqing Municipality, China
-
Shengjing Hospital
Shenyang, Liaoning, China
-
Shunde Hospital of Southern Medical University
Guangzhou, Guangdong, China
-
The Second Affiliated Hospital of Dalian Medical University
Dalian, Liaoning, China
-
Zhejiang University
Hanzhou, Zhejiang, China
-
the Sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, 501655, China